Skip to content

Source filing unavailable

Q2 2022 · —
Revenue—
Net Income-$29.35MN/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$1.76no prior Q2 2021 on fileN/M vs Q1 2022
Operating Income-$26,305,000—
Operating Cash Flowderived-$20,223,000—
Free Cash Flowderived-$25,025,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2022Q2 2021
Net Income-$29.35M$616.00K
EPS Diluted-$1.76—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR